Head and Neck Cancer

Panel 25 - (INTERACTIVE) Modern Therapy in Oropharyngeal Cancer: What is the Evidence for Immediate Implementation of Differing Strategies based upon HPV Status?

9/18/2019
1:15 PM - 2:30 PM
Location: Room W185

Session Type: Panel
1.25 AMA PRA Category 1 Credits™
1.25 CAMPEP Credits
1.5 MDCB Credits

This session will provide an overview of strengths/limitations of available studies and discuss ways to implement modern therapy in the era of HPV. The attendees will learn the current strategies for de-escalation and escalation in HPV-positive and HPV-negative oropharyngeal cancers. In addition, the session will provide evidence-based practices de-escalation or escalation strategies off protocol or on clinical trials. Finally, the practical ways to reconcile conflicting results from different studies will be addressed.

After moderators provide an overview, speakers will focus upon four topics:
- Treatment on and off protocol
- Treatment de-escalation strategies for HPV-positive tumors
- Treatment escalation with novel therapeutics for HPV-negative tumors
- Role of chemotherapy in early-stage disease treated with radiation

Learning Objectives:

Presentations:

Thomas Galloway, MD

Fox Chase Cancer Center

Disclosure:
Employment
Fox Chase Cancer Center: Attending Physician, Director of Clinical Research: Employee

Compensation
Varian: Speaker's Bureau

Leadership
Rare Tumors Task Force: Co-Chair

Presentation(s):

Send Email for Thomas Galloway

Matthew Katz, MD, FASTRO

Lowell General Hospital

Presentation(s):

Send Email for Matthew Katz


Assets

Panel 25 - (INTERACTIVE) Modern Therapy in Oropharyngeal Cancer: What is the Evidence for Immediate Implementation of Differing Strategies based upon HPV Status?



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Panel 25 - (INTERACTIVE) Modern Therapy in Oropharyngeal Cancer: What is the Evidence for Immediate Implementation of Differing Strategies based upon HPV Status?